Bristol Myers (BMY) Stock Forecast & Price Target

Compare

11,571 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMY Analyst Ratings

Hold

5 Buy

14 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Bristol

Myers

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$55.40

▲(15.27%Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Bristol Myers in the last 3 months. The average price target is $55.40 with a high forecast of $68.00 and a low forecast of $34.00. The average price target represents a 15.27% change from the last price of $48.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","42":"$42","51":"$51","60":"$60","69":"$69"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,42,51,60,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.89,48.51384615384615,50.137692307692305,51.761538461538464,53.385384615384616,55.00923076923077,56.63307692307692,58.25692307692307,59.88076923076923,61.504615384615384,63.128461538461536,64.7523076923077,66.37615384615384,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.89,47.54461538461538,48.199230769230766,48.853846153846156,49.50846153846154,50.16307692307692,50.817692307692305,51.472307692307695,52.12692307692308,52.78153846153846,53.43615384615384,54.09076923076923,54.745384615384616,{"y":55.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.89,45.89846153846154,44.90692307692308,43.91538461538462,42.923846153846156,41.932307692307695,40.940769230769234,39.949230769230766,38.957692307692305,37.966153846153844,36.97461538461538,35.98307692307692,34.99153846153846,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.85,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":47.7,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.52,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":52.46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$55.40

Lowest Price Target$34.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$53

Buy

10.28%

Upside

Upgraded

07/18/25

Bristol-Myers Squibb's solid financial performance and strategic initiatives in product launches and cost management drive an above-average score. While technical indicators and valuation are moderate, the positive earnings call, with improved guidance and operational efficiency, supports a favorable outlook despite regulatory and clinical trial risks.

Sean McCutcheonRaymond James

Raymond James

―

Hold

―

Reiterated

07/17/25

Raymond James Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Terence FlynnMorgan Stanley

Morgan Stanley

$34

Sell

-29.26%

Downside

Reiterated

07/16/25

Caution on Bristol-Myers Squibb: Reliance on Cobenfy Amid Uncertain Market Potential

Tim AndersonBank of America Securities

Bank of America Securities

$56

Hold

16.52%

Upside

Reiterated

07/14/25

Bristol-Myers Squibb (BMY) Receives a Hold from Bank of America Securities

Unknown AnalystBerenberg Bank

Not Ranked

Berenberg Bank

$55

Hold

14.44%

Upside

Reiterated

07/14/25

Berenberg Bank Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Trung HuynhUBS

UBS

$52

Hold

8.20%

Upside

Reiterated

07/11/25

UBS Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

David RisingerLeerink Partners

Leerink Partners

$115→$55

Buy

14.44%

Upside

Reiterated

07/09/25

Bristol-Myers Squibb (BMY) Gets a Buy from Leerink Partners

Evan SeigermanBMO Capital

BMO Capital

$53

Hold

10.28%

Upside

Reiterated

07/09/25

BMO Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Mohit BansalWells Fargo

Wells Fargo

$53

Hold

10.28%

Upside

Reiterated

07/09/25

Bristol-Myers Squibb: Hold Rating Amid Revenue Growth and Strategic Challenges

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Analysts Conflicted on These Healthcare Names: Centene (NYSE: CNC) and Bristol-Myers Squibb (NYSE: BMY)

David AmsellemPiper Sandler

Piper Sandler

$66

Buy

37.33%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Galapagos (NASDAQ: GLPG), OmniAb (NASDAQ: OABI) and Bristol-Myers Squibb (NYSE: BMY)

Chris SchottJ.P. Morgan

J.P. Morgan

$67

Buy

39.41%

Upside

Reiterated

06/16/25

J.P. Morgan Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$55

Hold

14.44%

Upside

Reiterated

06/12/25

Cantor Fitzgerald Remains a Hold on Bristol-Myers Squibb (BMY)

Geoff MeachamCiti

Citi

$51

Hold

6.12%

Upside

Reiterated

06/02/25

Bristol-Myers Squibb (BMY) Receives a Hold from Citi

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

06/02/25

Balanced Outlook on Bristol-Myers Squibb Amid Promising Oncology Pipeline and Market Challenges

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$53

Buy

10.28%

Upside

Upgraded

07/18/25

Sean McCutcheonRaymond James

Raymond James

―

Hold

―

Reiterated

07/17/25

Raymond James Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Terence FlynnMorgan Stanley

Morgan Stanley

$34

Sell

-29.26%

Downside

Reiterated

07/16/25

Caution on Bristol-Myers Squibb: Reliance on Cobenfy Amid Uncertain Market Potential

Tim AndersonBank of America Securities

Bank of America Securities

$56

Hold

16.52%

Upside

Reiterated

07/14/25

Bristol-Myers Squibb (BMY) Receives a Hold from Bank of America Securities

Unknown AnalystBerenberg Bank

Not Ranked

Berenberg Bank

$55

Hold

14.44%

Upside

Reiterated

07/14/25

Berenberg Bank Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Trung HuynhUBS

UBS

$52

Hold

8.20%

Upside

Reiterated

07/11/25

UBS Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

David RisingerLeerink Partners

Leerink Partners

$115→$55

Buy

14.44%

Upside

Reiterated

07/09/25

Bristol-Myers Squibb (BMY) Gets a Buy from Leerink Partners

Evan SeigermanBMO Capital

BMO Capital

$53

Hold

10.28%

Upside

Reiterated

07/09/25

BMO Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Mohit BansalWells Fargo

Wells Fargo

$53

Hold

10.28%

Upside

Reiterated

07/09/25

Bristol-Myers Squibb: Hold Rating Amid Revenue Growth and Strategic Challenges

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Analysts Conflicted on These Healthcare Names: Centene (NYSE: CNC) and Bristol-Myers Squibb (NYSE: BMY)

David AmsellemPiper Sandler

Piper Sandler

$66

Buy

37.33%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Galapagos (NASDAQ: GLPG), OmniAb (NASDAQ: OABI) and Bristol-Myers Squibb (NYSE: BMY)

Chris SchottJ.P. Morgan

J.P. Morgan

$67

Buy

39.41%

Upside

Reiterated

06/16/25

J.P. Morgan Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$55

Hold

14.44%

Upside

Reiterated

06/12/25

Cantor Fitzgerald Remains a Hold on Bristol-Myers Squibb (BMY)

Geoff MeachamCiti

Citi

$51

Hold

6.12%

Upside

Reiterated

06/02/25

Bristol-Myers Squibb (BMY) Receives a Hold from Citi

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

06/02/25

Balanced Outlook on Bristol-Myers Squibb Amid Promising Oncology Pipeline and Market Challenges

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol Myers

1 Month

xxx

Success Rate

12/22 ratings generated profit

Average Return

-0.41%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of -0.41% per trade.

3 Months

xxx

Success Rate

15/24 ratings generated profit

Average Return

+2.24%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +2.24% per trade.

1 Year

Terence FlynnMorgan Stanley

Success Rate

19/24 ratings generated profit

Average Return

+8.18%

reiterated a sell rating 3 days ago

Copying Terence Flynn's trades and holding each position for 1 Year would result in 79.17% of your transactions generating a profit, with an average return of +8.18% per trade.

2 Years

xxx

Success Rate

19/24 ratings generated profit

Average Return

+11.40%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 79.17% of your transactions generating a profit, with an average return of +11.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMY has received 7 Buy Ratings, 30 Hold Ratings, and 2 Sell Ratings. BMY average Analyst price target in the past 3 months is 55.40.

Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $1.06 with a range of $0.96 to $1.14. The previous quarter’s EPS was $1.80. BMY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year BMY has Preformed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $11.33B with a range of $11.11B to $11.47B. The previous quarter’s sales results were $11.20B. BMY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year BMY has Preformed in-line its overall industry.

BMY Stock Forecast FAQ

What is BMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 55.40.

What is BMY’s upside potential, based on the analysts’ average price target?

Bristol-Myers Squibb has 15.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMY a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Hold which is based on 5 buy ratings, 14 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s price target?

The average price target for Bristol-Myers Squibb is 55.40. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $34.00. The average price target represents 15.27% Increase from the current price of $48.06.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of BMY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bristol Myers (BMY) Stock Forecast & Price Target

BMY Analyst Ratings

BMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol Myers

BMY Analyst Recommendation Trends

BMY Financial Forecast

BMY Earnings Forecast

BMY Sales Forecast

BMY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts